<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Cypress Bioscience Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/cypress-bioscience-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CYPB) Cypress Bioscience Reports Wider Loss</title>
		<link>http://www.stockbloghub.com/2010/11/25/cypb-cypress-bioscience-reports-wider-loss/59647</link>
		<comments>http://www.stockbloghub.com/2010/11/25/cypb-cypress-bioscience-reports-wider-loss/59647#comments</comments>
		<pubDate>Fri, 26 Nov 2010 04:18:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexza Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXA]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[MDRNA Inc]]></category>
		<category><![CDATA[MRNA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59647</guid>
		<description><![CDATA[Cypress Bioscience, Inc. (CYPB) reported a net loss of 94 cents per share in the third quarter, significantly higher than the Zacks Consensus Estimate of a loss of 33 cents and the year ago loss of 12 cents. Despite an increase in revenues, higher operating expenses led to the wider loss in the reported quarter. Quarter in Detail Third-quarter revenues came in at $8 million, well above the Zacks Consensus Estimate of $5 million and 45.3% above the year-ago revenues of $5.5 million. Third quarter revenues consisted of $7.2 million in commercial revenues and $0.8 million in revenues under collaborative agreements. Commercial revenues of $7.2 million included royalty revenues of $3.2 million and $3.6 million in co-promotion reimbursement in connection with Savella. The co-promotion amount includes a one-time fee of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/25/cypb-cypress-bioscience-reports-wider-loss/59647/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GS) How to Unlock Gains From Corporate America</title>
		<link>http://www.stockbloghub.com/2010/10/27/gs-how-to-unlock-gains-from-corporate-america/56811</link>
		<comments>http://www.stockbloghub.com/2010/10/27/gs-how-to-unlock-gains-from-corporate-america/56811#comments</comments>
		<pubDate>Wed, 27 Oct 2010 20:46:19 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Diversified Investments]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EXTR]]></category>
		<category><![CDATA[Extreme Networks Inc.]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56811</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U’s Senior Analyst Wednesday, October 27, 2010: Issue #1375 Corporate America has a problem. It has too much cash. Hang on… having too much cash isn’t bad, right? On the contrary, in fact. It seems like a nice problem to have. But shareholders of companies that have massive wads of cash have a point in arguing that the executives should put the money to better use, rather than it earning next to nothing in the bank or in low-yielding investments. Typically, investors want that money put towards growing the business instead, usually via acquisitions or by returning it to the shareholders. But American companies aren’t listening. There is, however, a solution for everyday investors – and a company that could be primed to hand out a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/27/gs-how-to-unlock-gains-from-corporate-america/56811/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYPB) Cypress Bioscience Signs Deal With Marina Biotech</title>
		<link>http://www.stockbloghub.com/2010/09/16/cypb-cypress-bioscience-signs-deal-with-marina-biotech/49832</link>
		<comments>http://www.stockbloghub.com/2010/09/16/cypb-cypress-bioscience-signs-deal-with-marina-biotech/49832#comments</comments>
		<pubDate>Thu, 16 Sep 2010 16:22:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexza Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXA]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[MDRNA Inc]]></category>
		<category><![CDATA[MRNA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49832</guid>
		<description><![CDATA[Recently, Cypress Bioscience, Inc. (CYPB) announced that it has inked a deal with Marina Biotech, Inc. (MRNA). The deal, which allows Cypress to acquire Marina’s patent rights and technology for autism candidate, carbetocin, is expected to boost the central nervous system pipeline (CNS) at Cypress. The asset purchase agreement will see Cypress making an upfront payment of $750,000 to Marina. However, the value of the deal can increase to $27 million subject to the attainment of certain late-stage clinical and regulatory milestones Incorporatedluding the approval of the candidate by the US Food and Drug Administration (FDA). Moreover, Cypress will be responsible for financing all continuing development activities and will pay single-digit royalties to Marina on sales of the drug, if it hits the market. Carbetocin, an intranasal therapy, is a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/16/cypb-cypress-bioscience-signs-deal-with-marina-biotech/49832/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HPQ) Can $1.84 Trillion in Corporate Cash Save U.S. Economy?</title>
		<link>http://www.stockbloghub.com/2010/08/25/hpq-can-1-84-trillion-in-corporate-cash-save-u-s-economy/49288</link>
		<comments>http://www.stockbloghub.com/2010/08/25/hpq-can-1-84-trillion-in-corporate-cash-save-u-s-economy/49288#comments</comments>
		<pubDate>Wed, 25 Aug 2010 17:07:30 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Diversified Computer Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[3PAR]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bhp Billiton Limited]]></category>
		<category><![CDATA[Bluelinx Holdings Inc]]></category>
		<category><![CDATA[BXC]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[PAR]]></category>
		<category><![CDATA[POT]]></category>
		<category><![CDATA[Potash Corporation of Saskatchewan Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49288</guid>
		<description><![CDATA[by Marc Lichtenfeld, Advisory Panelist Wednesday, August 25, 2010: Issue #1331 Scan the headlines these days and a lengthy list of negatives will stare you in the face. Stubbornly high numbers of unemployed Americans. The gargantuan (and ever-increasing) budget deficit. And just yesterday, news that existing home sales recorded a bone-jarring 27% plunge in July, twice as much as forecast. Things are just plain awful, aren’t they? Well, not everything. Despite the many negatives, there are some positives (just don’t hold your breath for the media to tell you about them.) For example, non-financial S&#38;P 500 companies have $837 billion in cash on their balance sheets. That’s a record and is up 26% from a year ago. (My colleague Louis Basenese recently quoted a figure from Moody’s, which claims non-financial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/25/hpq-can-1-84-trillion-in-corporate-cash-save-u-s-economy/49288/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Labs Tops Consensus Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/07/20/frx-forest-labs-tops-consensus-earnings-estimates/44133</link>
		<comments>http://www.stockbloghub.com/2010/07/20/frx-forest-labs-tops-consensus-earnings-estimates/44133#comments</comments>
		<pubDate>Tue, 20 Jul 2010 20:40:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44133</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) reported earnings per share of 95 cents for the first quarter of fiscal 2011, well above the Zacks Consensus Estimate of 86 cents and the year-earlier earnings of 87 cents. Including the impact of a charge related to investigations being carried out by the US Department of Justice (DoJ) and a new product licensing fee, earnings came in at 39 cents per share. First quarter revenues increased 5.8% to $1.07 billion, with net sales increasing 7.6% to $1 billion. While contract revenues slipped 16.6% to $39.8 million, interest income declined 42.5% to $7 million. The Quarter in Detail First quarter product revenues increased 7.6% to $1,020.1 million. Although Lexapro revenues remained flat at $565.2 million, Namenda, which is approved for the treatment of moderate and severe ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/frx-forest-labs-tops-consensus-earnings-estimates/44133/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories&#8217; Earnings Report Meets &#8211; Forward Guidance Drops</title>
		<link>http://www.stockbloghub.com/2010/04/21/frx-forest-laboratories-earnings-report-meets-forward-guidance-drops/34459</link>
		<comments>http://www.stockbloghub.com/2010/04/21/frx-forest-laboratories-earnings-report-meets-forward-guidance-drops/34459#comments</comments>
		<pubDate>Wed, 21 Apr 2010 22:20:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34459</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) reported earnings per share of 83 cents for the fourth quarter of fiscal 2010, in-line with the Zacks Consensus Estimate, and above the year-ago earnings of 76 cents. Full-year earnings came in at $3.51, up from fiscal 2009 earnings of $3.45. While fourth quarter revenues increased 9.4% to $1.06 billion, full-year revenues increased 6.9% to $4.2 billion. The Quarter in Detail Fourth quarter product revenues increased 11% to $996 million. Although Lexapro revenues grew only 1.4% to $556.3 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $297.9 million, recording a growth of 22.2% from the year-ago period. Improved patient access and increased promotional efforts should help keep Namenda sales strong. Bystolic, Forest’s beta-blocker for the treatment of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/frx-forest-laboratories-earnings-report-meets-forward-guidance-drops/34459/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Labs Earnings Preview &#8211; Third Quarter Highlights</title>
		<link>http://www.stockbloghub.com/2010/04/14/frx-forest-labs-earnings-preview-third-quarter-highlights/33718</link>
		<comments>http://www.stockbloghub.com/2010/04/14/frx-forest-labs-earnings-preview-third-quarter-highlights/33718#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:48:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33718</guid>
		<description><![CDATA[Forest Labs (FRX) is all set to announce its fourth quarter and full year fiscal 2010 results on Apr 20. The company expects to report fiscal 2010 earnings towards the higher end of its guidance range of $3.40 &#8211; $3.50 per share on revenues of $4.1 billion. Third Quarter Highlights Forest reported strong earnings of 97 cents per share in the third quarter, which topped the Zacks Consensus Estimate by 11 cents. Total revenues increased 6.7% to $1.06 billion with product revenues increasing 8.4% to $997 million. Although Lexapro sales declined 0.5% to $582.6 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $282.5 million, recording a growth of 17.3% from the year-ago period. Improved patient access and increased promotional efforts should help ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/frx-forest-labs-earnings-preview-third-quarter-highlights/33718/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYPB) Cypress Bioscience&#8217;s Fourth Quarter Loss Narrows</title>
		<link>http://www.stockbloghub.com/2010/04/01/cypb-cypress-biosciences-fourth-quarter-loss-narrows/32654</link>
		<comments>http://www.stockbloghub.com/2010/04/01/cypb-cypress-biosciences-fourth-quarter-loss-narrows/32654#comments</comments>
		<pubDate>Thu, 01 Apr 2010 21:41:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32654</guid>
		<description><![CDATA[Cypress Bioscience, Inc. (CYPB) reported a net loss of 13 cents per share in the fourth quarter Incorporatedluding the impact of a $1.1 million goodwill impairment charge associated with the company’s personalized medicine services business. Excluding this charge, net loss came in at 10 cents, much better than the year-ago loss of 19 cents and the Zacks Consensus Estimate of -13 cents. Despite a significant increase in full year 2009 revenues, net loss for the full year increased to 74 cents Incorporatedluding the impact of the goodwill impairment charge, from the loss of 48 cents reported in 2008. Excluding the impact of the goodwill impairment charge, net loss for 2009 came in at 71 cents. The higher loss was due to higher operating expenses on account of costs associated with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/cypb-cypress-biosciences-fourth-quarter-loss-narrows/32654/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Beats Earnings Expectations</title>
		<link>http://www.stockbloghub.com/2010/01/19/frx-forest-laboratories-beats-earnings-expectations/25291</link>
		<comments>http://www.stockbloghub.com/2010/01/19/frx-forest-laboratories-beats-earnings-expectations/25291#comments</comments>
		<pubDate>Tue, 19 Jan 2010 23:36:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25291</guid>
		<description><![CDATA[This morning, Forest Laboratories, Inc. (FRX), reported earnings per share of 97 cents for the third quarter of fiscal 2010, well above the Zacks Consensus Estimate of 86 cents. Total revenues increased 6.7% to $1.06 billion with product revenues increasing 8.4% to $997 million. Although Lexapro sales declined 0.5% to $582.6 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $282.5 million, recording a growth of 17.3% from the year-ago period. Improved patient access and increased promotional efforts should help keep Namenda sales strong. Bystolic, Forest’s beta-blocker for the treatment of hypertension, posted sales of $47.5 million. This was significantly higher than the year-ago sales of $21 million. Contract revenue, consisting primarily of Benicar co-promotion income Incorporatedreased 6.5% to $55.8 million. Forest’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/19/frx-forest-laboratories-beats-earnings-expectations/25291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYPB) Cypress Bioscience, Inc Beats Consensus &#8211; Loss Widens</title>
		<link>http://www.stockbloghub.com/2009/11/11/cypb-cypress-bioscience-inc-beats-consensus-loss-widens/20302</link>
		<comments>http://www.stockbloghub.com/2009/11/11/cypb-cypress-bioscience-inc-beats-consensus-loss-widens/20302#comments</comments>
		<pubDate>Wed, 11 Nov 2009 21:15:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20302</guid>
		<description><![CDATA[Cypress Bioscience, Inc. (CYPB) reported a net loss of 14 cents per share in the third quarter, 6 cents better than the Zacks Consensus Estimate of a net loss of 20 cents. Although revenues increased significantly from the year-ago period, net loss was higher due to higher operating expenses mainly due to costs associated with the setting up of the company’s commercial organization. Net loss in the year-ago period was 11 cents. Total revenues came in at $6.1 million in the reported quarter, up significantly from the year-ago revenues of $0.9 million. Third quarter revenues of $6.1 million consisted of $5.2 million in commercial revenues, $0.8 million in revenues under collaborative agreements, and $0.075 million in revenues from the company’s personalized medicine service business. Commercial revenues of $5.2 million included ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/cypb-cypress-bioscience-inc-beats-consensus-loss-widens/20302/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Reports In-Line Earnings</title>
		<link>http://www.stockbloghub.com/2009/10/20/frx-forest-laboratories-reports-in-line-earnings/18274</link>
		<comments>http://www.stockbloghub.com/2009/10/20/frx-forest-laboratories-reports-in-line-earnings/18274#comments</comments>
		<pubDate>Tue, 20 Oct 2009 22:56:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18274</guid>
		<description><![CDATA[This morning, Forest Laboratories, Inc. (FRX), reported earnings per share of 85 cents for the second quarter of fiscal 2010, in-line with the Zacks Consensus Estimate. Product sales increased 4% to $962.7 million. Although Lexapro sales declined 3.1% to $566 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $275.3 million, recording a growth of 11.9% from the year-ago period. Improved patient access and increased promotional efforts should help keep Namenda sales strong. Bystolic, Forest’s beta-blocker for the treatment of hypertension, posted sales of $40.7 million. This was significantly higher than the year ago sales of $14.2 million. Contract revenue, consisting primarily of Benicar co-promotion income Incorporatedreased 7.2% to $50.6 million. Forest’s most recent product launch, Savella, which is approved for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/frx-forest-laboratories-reports-in-line-earnings/18274/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

